Contact this trialFirst, we need to learn more about you.
Chemotherapy
Pembrolizumab + Trastuzumab + Chemotherapy for Gastric Cancer
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial will compare the efficacy of two different treatments for HER2-positive gastric cancer. The first treatment is pembrolizumab in combination with standard chemotherapy, and the second is trastuzumab in combination with standard chemotherapy. The hypothesis of the study is that pembrolizumab is superior to trastuzumab in terms of progression free survival and overall survival.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service